Drug Therapies for High Cholesterol

New England CEPAC
October 27, 2015 10am-4pm

Joseph B. Martin Conference Center at Harvard Medical School

77 Avenue Louis Pasteur

Boston, MA 02115

Cardiovascular disease (CVD) is the most common cause of death in the United States and approximately one third of American adults have CVD. Low density lipoprotein cholesterol (LDL) is a major modifiable risk factor for myocardial infarction, stroke, and death from cardiovascular disease. The use of statins to decrease LDL has contributed to the marked decline in death from CVD since 1950, but some patients are not able to tolerate statins and others have inadequate reductions in LDL. In June 2015, the FDA advisory panel voted to recommend approval of two human monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) in the blood and markedly reduce LDL cholesterol levels.

Download ICER's New Evidence Update on Evolocumab here.

Key Dates

Associated Materials

07/07/2015

09/08/2015 – 09/22/2015

Public comments received on the Draft Evidence Report.


09/08/2015

09/08/2015

10/06/2015

10/06/2015

10/06/2015

ICER’s response to public comments received on the draft evidence report.


10/21/2015

Research protocol posted to Open Science Framework: https://osf.io/7awvd/


10/27/2015

10/27/2015

11/25/2015

11/25/2015
Action Guide For Clinicians, Payers, and Policymakers

11/25/2015
Action Guide For Patients